It can inhibit prostate cancer by regulating the expression of Skp2, P27Kip1, P21Cip1 and P53, reduce VEGF secretion in MDA-231 cells in a dose-dependent manner16–18; up-regulate E2F-1, P53 and P21 expression in cervical cancer cells; and change the expression of Cyclin A, Cyclin B and Cyclin C in the cell cycle19. Here, TP53 is linked to prostate cancer.